{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:24:22Z","timestamp":1769729062605,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020477","name":"Edward Via College of Osteopathic Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020477","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103739","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:23:52Z","timestamp":1760030632000},"page":"103739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting neutral sphingomyelinase 2 by cambinol decreases cell proliferation and migration of metastatic castration\u2013resistant prostate cancer cells"],"prefix":"10.1016","volume":"392","author":[{"given":"Dalal","family":"Dawud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malvina","family":"Kartamyshev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzair M.","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0348","authenticated-orcid":false,"given":"Zakaria Y.","family":"Abd Elmageed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jpet.2025.103739_bib2","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/j.clgc.2017.09.015","article-title":"Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey","volume":"16","author":"Drudge-Coates","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2025.103739_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"20","key":"10.1016\/j.jpet.2025.103739_bib4","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1200\/JCO.2004.11.514","article-title":"Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08\/88","volume":"22","author":"Studer","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103739_bib5","first-page":"336","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer","volume":"30","author":"Luo","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.jpet.2025.103739_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103739_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.21037\/cco-24-82","article-title":"Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2024","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103739_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.23304","article-title":"Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jpet.2025.103739_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.acr.2018.04.010","article-title":"Neutral sphingomyelinases in cancer: friend or foe?","volume":"140","author":"Clarke","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"7","key":"10.1016\/j.jpet.2025.103739_bib10","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.drudis.2021.03.025","article-title":"Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases","volume":"26","author":"Tallon","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103739_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101936","article-title":"Roles and therapeutic targeting of ceramide metabolism in cancer","volume":"83","author":"Wajapeyee","year":"2024","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.ajpath.2014.01.009","article-title":"Ceramide-activated phosphatase mediates fatty acid-induced endothelial VEGF resistance and impaired angiogenesis","volume":"184","author":"Mehra","year":"2014","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103739_bib13","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-07-4881","article-title":"Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development","volume":"14","author":"Tran","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.62347\/JWMX3035","article-title":"Decoding the secrets of small extracellular vesicle communications: exploring the inhibition of vesicle-associated pathways and interception strategies for cancer treatment","volume":"14","author":"Shams","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.jpet.2025.103739_bib15","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.62347\/XXXA3182","article-title":"Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with enzalutamide","volume":"14","author":"Shams","year":"2024","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11033-024-10203-6","article-title":"Role of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer","volume":"52","author":"Gupta","year":"2025","journal-title":"Mol Biol Rep"},{"issue":"4","key":"10.1016\/j.jpet.2025.103739_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1124\/mol.108.046250","article-title":"Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells","volume":"74","author":"Clarke","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103739_bib18","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbamem.2006.06.025","article-title":"Neutral sphingomyelinases and nSMase2: bridging the gaps","volume":"1758","author":"Clarke","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib19","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-11-0705","article-title":"Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2\/ceramide induction","volume":"11","author":"Meyers-Needham","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.jpet.2025.103739_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/17460875.3.3.273","article-title":"Ceramide signaling in cancer and stem cells","volume":"3","author":"Bieberich","year":"2008","journal-title":"Future Lipidol"},{"issue":"43","key":"10.1016\/j.jpet.2025.103739_bib21","doi-asserted-by":"crossref","first-page":"41128","DOI":"10.1074\/jbc.M206747200","article-title":"Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase","volume":"277","author":"Luberto","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124481","article-title":"Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties","volume":"10","author":"Figuera-Losada","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.jpet.2025.103739_bib23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"W1","key":"10.1016\/j.jpet.2025.103739_bib24","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"6352","key":"10.1016\/j.jpet.2025.103739_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan2507","article-title":"A pathology atlas of the human cancer transcriptome","volume":"357","author":"Uhlen","year":"2017","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.jpet.2025.103739_bib26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/pros.23190","article-title":"Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line","volume":"76","author":"Shourideh","year":"2016","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.jpet.2025.103739_bib27","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3390\/cancers12082300","article-title":"Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition","volume":"12","author":"Gaballa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jpet.2025.103739_bib28","first-page":"4015","article-title":"Small extracellular vesicle-associated miR-6068 promotes aggressive phenotypes of prostate cancer through miR-6068\/HIC2\/SIRT1 axis","volume":"12","author":"Gaballah","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103739_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41391-019-0134-5","article-title":"MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer","volume":"22","author":"Nickols","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.jpet.2025.103739_bib31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/pharmaceutics13081195","article-title":"Inhibitors of the PI3K\/Akt\/mTOR pathway in prostate cancer chemoprevention and intervention","volume":"13","author":"Roudsari","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jpet.2025.103739_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2353\/ajpath.2009.080727","article-title":"NF-kappaB regulates androgen receptor expression and prostate cancer growth","volume":"175","author":"Zhang","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jpet.2025.103739_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107538","article-title":"NF-kappaB signaling promotes castration-resistant prostate cancer initiation and progression","volume":"211","author":"Thomas-Jardin","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103739_bib34","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2326-6066.CIR-20-0342","article-title":"Neutral sphingomyelinase 2 heightens anti-melanoma immune responses and anti-PD-1 therapy efficacy","volume":"9","author":"Montfort","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"7503","key":"10.1016\/j.jpet.2025.103739_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13041-021-00776-9","article-title":"Pharmacological inhibition of nSMase2 reduces brain exosome release and alpha-synuclein pathology in a Parkinson's disease model","volume":"14","author":"Zhu","year":"2021","journal-title":"Mol Brain"},{"issue":"8","key":"10.1016\/j.jpet.2025.103739_bib38","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/0008-5472.CAN-05-3617","article-title":"Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes","volume":"66","author":"Heltweg","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103739_bib39","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/biomedicines11061624","article-title":"Sirtuin inhibitor cambinol induces cell differentiation and differently interferes with SIRT1 and 2 at the substrate binding site","volume":"11","author":"Giordano","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jpet.2025.103739_bib40","first-page":"83","article-title":"The histone deacetylase inhibitor cambinol prevents acidic pH(e)-induced anterograde lysosome trafficking independently of sirtuin activity","volume":"3","author":"Dykes","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.jpet.2025.103739_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105734","article-title":"Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV","volume":"169","author":"Zhu","year":"2022","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.1016\/j.jpet.2025.103739_bib42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41419-018-0709-4","article-title":"Activation of neutral sphingomyelinase 2 by starvation induces cell-protective autophagy via an increase in Golgi-localized ceramide","volume":"9","author":"Back","year":"2018","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.jpet.2025.103739_bib43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","article-title":"Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth","volume":"8","author":"Wang","year":"2014","journal-title":"Cell Rep"},{"issue":"16","key":"10.1016\/j.jpet.2025.103739_bib44","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1158\/0008-5472.CAN-08-0107","article-title":"The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103739_bib45","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6602851","article-title":"Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse","volume":"93","author":"Domingo-Domenech","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73912-5","article-title":"Neutral sphingomyelinase 2 regulates inflammatory responses in monocytes\/macrophages induced by TNF-alpha","volume":"10","author":"Al-Rashed","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpet.2025.103739_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-015-0168-z","article-title":"Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK\/JNK and MEK\/ERK1\/2-mediated targeting NF-kappaB\/p65 and MUC1-C","volume":"34","author":"Li","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103739_bib48","first-page":"1851","article-title":"Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate","volume":"35","author":"Rogers","year":"2015","journal-title":"Anticancer Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:19:06Z","timestamp":1764058746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402523"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103739","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting neutral sphingomyelinase 2 by cambinol decreases cell proliferation and migration of metastatic castration\u2013resistant prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103739"}}